1例卡瑞利珠单抗致重度心肌炎不良反应及临床分析

doi:10.3969/j.issn.2095-1264.2022.01.22

首页 > 过刊浏览>2022年第1期 >136-140. DOI:10.3969/j.issn.2095-1264.2022.01.22

1例卡瑞利珠单抗致重度心肌炎不良反应及临床分析
DOI:
                        10.3969/j.issn.2095-1264.2022.01.22
                    
作者:
                        
                        
                    
作者单位:1.东胜区人民医院 药剂科，内蒙古 鄂尔多斯，017000;2.鄂尔多斯市中心医院 药剂科， 内蒙古 鄂尔多斯，017000
作者简介:闫丽荣，女，主管药师，研究方向：药事管理、药物不良反应。
通讯作者:陈刚，男，主管药师，研究方向：抗肿瘤药物。
中图分类号:R734.2;R730.6
基金项目:★鄂尔多斯市医学重点学科建设资助项目。

Clinical analysis of a case of severe myocarditis induced by camrelizumab^★

Author:

Affiliation:

1.Pharmacy Department, Dongsheng People's Hospital, Ordos, Inner Mongolia, 017000, China;2.Pharmacy Department, Ordos Central Hospital, Ordos, Inner Mongolia, 017000, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

免疫检查点抑制剂在临床的使用范围逐渐扩大，可明显延长患者生存期，但其独特的免疫相关不良反应也应该引起人们的重视。本文分析1例61岁晚期肺癌女性患者使用卡瑞利珠单抗（200 mg， ivgtt q2w）12天后，出现头晕并逐渐加重，考虑为PD-1抑制剂引起的免疫相关性肌炎累及心肌、伴横纹肌溶解的重叠综合征，予以激素冲击联合免疫球蛋白抗炎及其他对症治疗，但最终结局并未好转。

Abstract:

Immune checkpoint inhibitors are widely used in clinic and they can significantly prolong the survival of patients, but their unique immune-related adverse reactions should also be paid attention to. In this paper, we discussed a case of 61-year-old female patient with advanced lung cancer received camrelizumab (200 mg, ivgtt q2w) treatment. The patient appeared dizzy after 12 days of camrelizumab treatment, and it was gradually aggravated. It was considered to be immune-related myositis involving myocardium and rhabdomyolysis overlap syndrome caused by PD-1 inhibitor. The patient was given steroid therapy, immunoglobulin and other symptomatic treatment. Unfortunately, the condition of this patient was not improved after treatment.